Archived Insight | September 26, 2019

New Guidance on Enforcement of MHPAEA

On September 5, 2019, the federal departments implementing the Mental Health Parity and Addiction Equity Act (MHPAEA) — the Departments of Health and Human Services, Labor and Treasury (the Departments) —issued answers to Frequently Asked Questions (FAQs) regarding implementation of MHPAEA, the 21st Century Cures Act (Cures Act) and the SUPPORT for Patient and Communities Act (Support Act).

These FAQs make final previously proposed FAQ guidance issued by the Departments in 2018.

The Departments also issued a disclosure template that may be used to request mental health and substance use disorder benefit information from a plan.

Download Now

Questions about this update?

We're here to help. Get in touch.

Speak with Us

See more insights

Asia Female Pharmacist Using Digital Tablet While Taking Inventory

New Requirements for PBM Reporting and Fee Disclosures

The Consolidated Appropriations Act of 2026 makes significant reforms to pharmacy benefit manager practices. See the impact on health plan sponsors.

Compliance, Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate, Pharmaceutical

Read Full Insight

IRS Issues New Model Notices for Eligible Rollovers

Retirement plan administrators: There are two new model rollover notices for eligible rollover distributions, which you can start using now.

Retirement, Compliance, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate

Read Full Insight

Couple Calculating Bills At Home Using Tablet And Calculator

Proposed Rule on Healthcare Price Transparency Disclosures

A proposed rule would change price transparency requirements for health plans and health insurers, including updated machine-readable file standards.

Health, Compliance, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.